| 2017 |
Coller, J., Bowen, J., Ball, I., Wardill, H., van Sebille, Y., Stansborough, R. ... Gibson, R. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79, 2, 431-434. 10.1007/s00280-016-3223-3 |
| 2017 |
Van Sebille, Y., Gibson, R., Wardill, H., Secombe, K., Ball, I., Keefe, D. ... Bowen, J. (2017). Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 140, 12, 2820-2829. 10.1002/ijc.30699 |
| 2016 |
Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Logan, R. & Bowen, J. (2016). A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 241, 13, 1386-1394. 10.1177/1535370216640932 |
| 2016 |
Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I. ... Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15, 11, 2767-2779. 10.1158/1535-7163.MCT-16-0330 |
| 2016 |
Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I. ... Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15, 6, 1376-1386. 10.1158/1535-7163.MCT-15-0990 |
